Evidence map›Paper›PMID 28542444›Full record

ArticlePloS one2017

Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.

Rizwan S Akhtar, Sharon X Xie, Yin J Chen, Jacqueline Rick, Rachel G Gross, Ilya M Nasrallah, Vivianna M Van Deerlin, John Q Trojanowski, Alice S Chen-Plotkin, Howard I Hurtig and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Impact of 6-OHDA injection and microtrauma in the ratHistology and histopathology · 2025
    Article
  8. The role ofFrontiers in neuroscience · 2025
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.Movement disorders : official journal of the Movement Disorder Society · 2020
    Review
  19. Article
  20. Amyloid-β and Parkinson's disease.Journal of neurology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Rizwan S AkhtarDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID http://orcid.org/0000-0001-9808-7228
Sharon X XieDepartment of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Yin J ChenDepartment of Radiology, Division of Nuclear Medicine and Clinical Molecular Imaging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Jacqueline RickDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Rachel G GrossDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Ilya M NasrallahDepartment of Radiology, Division of Nuclear Medicine and Clinical Molecular Imaging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Vivianna M Van DeerlinCenter for Neurodegenerative Disease Research and Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
John Q TrojanowskiCenter for Neurodegenerative Disease Research and Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Alice S Chen-PlotkinDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Howard I HurtigDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Andrew D SiderowfDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Jacob G DubroffDepartment of Radiology, Division of Nuclear Medicine and Clinical Molecular Imaging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Daniel WeintraubDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
University of Pennsylvania · USInstitute on Aging · USMental Illness Research, Education and Clinical Centers · US

Funding

UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
Project IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9M
Unbiased Approaches to Novel Biomarker Discovery in Parkinson's DiseaseU01NS082134 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI CHEN-PLOTKIN, ALICE S · 2012 to 2016
$1.8M
The influence of nicotinic hepatic metabolism on neuroreceptor substrates of nicotine addictionK23DA038726 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI DUBROFF, JACOB · 2016 to 2020
$964k
Alpha-synuclein biomarkers in Parkinson diseaseK08NS093127 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI AKHTAR, RIZWAN SMEER · 2015 to 2019
$918k
Towards a blood-based diagnostic panel for confirmation of Parkinson's diseaseU01NS097056 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI CHEN-PLOTKIN, ALICE S · 2017 to 2019
$785k
18F-AV-45 PET Imaging of Amyloid in PD with Cognitive ImpairmentR43NS063607 · NINDS · AVID RADIOPHARMACEUTICALS, INC. · PI SKOVRONSKY, DANIEL M. · 2008 to 2009
$507k
NIA NIH HHS P30 AG010124NIDA NIH HHS K23 DA038726NINDS NIH HHS K08 NS093127NINDS NIH HHS P50 NS053488NINDS NIH HHS R43 NS063607NINDS NIH HHS U01 NS082134NINDS NIH HHS U01 NS097056
6 · The paper itself

Abstract

Parkinson disease patients develop clinically significant cognitive impairment at variable times over their disease course, which is often preceded by milder deficits in memory, visuo-spatial, and executive domains. The significance of amyloid-β accumulation to these problems is unclear. We hypothesized that amyloid-β PET imaging by 18F-florbetapir, a radiotracer that detects fibrillar amyloid-β plaque deposits, would identify subjects with global cognitive impairment or poor performance in individual cognitive domains in non-demented Parkinson disease patients. We assessed 61 non-demented Parkinson disease patients with detailed cognitive assessments and 18F-florbetapir PET brain imaging. Scans were interpreted qualitatively (positive or negative) by two independent nuclear medicine physicians blinded to clinical data, and quantitatively by a novel volume-weighted method. The presence of mild cognitive impairment was determined through an expert consensus process using Level 1 criteria from the Movement Disorder Society. Nineteen participants (31.2%) were diagnosed with mild cognitive impairment and the remainder had normal cognition. Qualitative 18F-florbetapir PET imaging was positive in 15 participants (24.6%). Increasing age and presence of an APOE ε4 allele were associated with higher composite 18F-florbetapir binding. In multivariable models, an abnormal 18F-florbetapir scan by expert rating was not associated with a diagnosis of mild cognitive impairment. However, 18F-florbetapir retention values in the posterior cingulate gyrus inversely correlated with verbal memory performance. Retention values in the frontal cortex, precuneus, and anterior cingulate gyrus retention values inversely correlated with naming performance. Regional cortical amyloid-β amyloid, as measured by 18F-florbetapir PET, may be a biomarker of specific cognitive deficits in non-demented Parkinson disease patients.

Indexed as

AgedAlzheimer DiseaseAmyloidAmyloid beta-PeptidesAniline CompoundsBrainCognitionCognition DisordersDementiaEthylene GlycolsFemaleHumansMaleMiddle AgedParkinson DiseasePlaque, AmyloidAmyloidAmyloid beta-PeptidesAniline CompoundsEthylene Glycolsflorbetapir

Identifiers

PMID28542444
PMCPMC5444629
OpenAlexW2618847690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.